Barclays PLC Grows Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Barclays PLC increased its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) by 136.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 190,243 shares of the company's stock after acquiring an additional 109,931 shares during the quarter. Barclays PLC owned approximately 0.21% of Myriad Genetics worth $5,210,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MYGN. Loomis Sayles & Co. L P increased its stake in Myriad Genetics by 153.7% in the third quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company's stock valued at $59,973,000 after purchasing an additional 1,326,497 shares during the period. Iron Triangle Partners LP purchased a new position in shares of Myriad Genetics during the third quarter worth about $11,007,000. State Street Corp increased its position in Myriad Genetics by 8.3% in the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company's stock valued at $128,827,000 after acquiring an additional 359,685 shares during the period. Point72 Asset Management L.P. raised its stake in Myriad Genetics by 26.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company's stock valued at $29,135,000 after acquiring an additional 224,255 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its position in Myriad Genetics by 47.8% during the 3rd quarter. Fisher Asset Management LLC now owns 602,842 shares of the company's stock worth $16,512,000 after acquiring an additional 195,094 shares during the period. Hedge funds and other institutional investors own 99.02% of the company's stock.

Myriad Genetics Price Performance

MYGN stock traded up $0.19 on Friday, reaching $13.36. The company had a trading volume of 3,971,786 shares, compared to its average volume of 772,582. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The company's fifty day moving average is $17.70 and its 200 day moving average is $23.25. The company has a market cap of $1.22 billion, a P/E ratio of -10.28 and a beta of 1.87. Myriad Genetics, Inc. has a 1 year low of $12.87 and a 1 year high of $29.30.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MYGN. Leerink Partnrs lowered Myriad Genetics from a "strong-buy" rating to a "hold" rating in a report on Monday, December 9th. UBS Group initiated coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $18.00 price objective on the stock. StockNews.com cut shares of Myriad Genetics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Morgan Stanley dropped their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Monday, November 18th. Finally, Leerink Partners downgraded shares of Myriad Genetics from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $24.27.

Insider Activity

In related news, CEO Paul J. Diaz sold 15,000 shares of the company's stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the transaction, the chief executive officer now owns 962,378 shares of the company's stock, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.10% of the company's stock.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.